View Clinical Trial (Medical Research Study)

A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer - NCT00642018-38138(Clinical Trial 210888)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Memphis
State:  
TN
Zip Code: 38138
Conditions: Prostate Cancer
Purpose: The primary purpose of this study is to determine whether LY2181308 in combination with docetaxel is safe and effective treatment for hormone refractory prostate cancer patients.
Study summary:
Criteria: Inclusion Criteria: - Histologically or cytologically confirmed adenocarcinoma of the prostate which is metastatic and/or unresectable - Hormone refractory prostate cancer defined as progressive based by documented 2 increase PSA values over a previous reference value. - ECOG status 0-2 - Adequate hematological functions, liver and renal functions Exclusion Criteria: - Known hypersensitivity to docetaxel or taxane therapy - Documented central nervous system or leptomeningeal metastasis at time of study entry - Had prior treatment with chemotherapy, bone seeking radionucleides in past 6 weeks prior to enrollment, or radiotherapy involving more than 25% of marrow producing area. - Evidence of painful and/or destructive bone metastases for which radiation therapy, biophosphonates or boneseeking radionucleides are necessary. - Have received treatment in the last 30 day with a drug which has not received regulatory approval for any indication at the time of study entry.
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: October 22, 2010
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.